Jerry Tanner
Endocrinology, Diabetes & Metabolism · Anchorage, AKNPI 1962580480
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,338 of the $17,618 with a category attached, or 81.4%. Novo Nordisk accounts for 79.5% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $14,737 and has fallen 99.4% since, to $90 in 2025.
Across 97 payments — averaging $181.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$14K
- Medtronic$1K
- Senseonics, Incorporated$826
- Novartis$460
- Sanofi-aventis U.S. LLC$174
- Lilly USA, LLC$130
- plus $554 from 16 others
What the payments were for
- Speaking & faculty fees$14,33881%
- Travel & lodging$1,0656%
- Food & beverage$2,21413%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $14,012 |
| Medtronic(2 entities) | 17 | $1,462 |
| Senseonics, Incorporated | 2 | $826 |
| Novartis | 18 | $460 |
| Sanofi-aventis U.S. LLC | 8 | $174 |
| Lilly USA, LLC | 7 | $130 |
| Amgen | 4 | $130 |
| AbbVie | 3 | $66 |
| Tandem Diabetes Care, Inc. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| GSK | 2 | $43 |
| Boehringer Ingelheim | 2 | $32 |
| Abiomed | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Bayer | 1 | $17 |
| RGH Enterprises LLC | 1 | $16 |
| Merck | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tresiba$7,896
- Ozempic$5,332
- MINIMED 780G$895
- Eversense$800
How this compares
Too few endocrinology, diabetes & metabolism providers in Alaskato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 261 | $363,032 |
| JardianceEmpagliflozin | 153 | $186,885 |
| Tresiba Flextouch U-200Insulin Degludec | 117 | $128,499 |
| Repatha SureclickEvolocumab | 87 | $94,302 |
| OzempicSemaglutide | 65 | $83,424 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $55,020 |
| TrulicityDulaglutide | 29 | $35,381 |
| FarxigaDapagliflozin Propanediol | 17 | $27,660 |
| JanuviaSitagliptin Phosphate | 28 | $25,710 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 18 | $22,867 |
| Novolog FlexpenInsulin Aspart | 60 | $21,778 |
| Praluent PenAlirocumab | 17 | $19,414 |
| ProliaDenosumab | 11 | $18,813 |
| EliquisApixaban | 11 | $18,350 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $17,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $130 | $404,172309 claims |
| Boehringer IngelheimJardiance, Tradjenta | $32 | $194,247164 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog, Novolog Mix 70-30 | $14,012 | $116,692119 claims |
| AstraZenecaFarxiga | $20 | $27,66017 claims |
| MerckJanuvia | $15 | $25,71028 claims |
| AmgenProlia | $130 | $18,81311 claims |
| AbbVieSynthroid | $66 | $12,702114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Anchorage
- Jeffrey MedlandAnchorage$9K
- Janice KovalAnchorage$6K
- Jeanne BonarAnchorage$2K
- Konrad KaltenbornAnchorage$1K
- Patrick NolanAnchorage$986
- Samuel AbbateWasilla$2K
- Muhammad AhmedFairbanks$1K
- Laily MahooziCordova$83
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.